WO2008009858A3 - Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009858A3
WO2008009858A3 PCT/FR2007/051685 FR2007051685W WO2008009858A3 WO 2008009858 A3 WO2008009858 A3 WO 2008009858A3 FR 2007051685 W FR2007051685 W FR 2007051685W WO 2008009858 A3 WO2008009858 A3 WO 2008009858A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
elovl5
hyperseborrhoea
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051685
Other languages
English (en)
Other versions
WO2008009858A2 (fr
WO2008009858A9 (fr
Inventor
Fernand Labrie
Mohamed El-Alfy
Van Luu-The
Ezequiel L Calvo
Pascal Collette
Sophie Deret
Michel Rivier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to EP07823604A priority Critical patent/EP2046979A2/fr
Priority to CA002656891A priority patent/CA2656891A1/fr
Publication of WO2008009858A2 publication Critical patent/WO2008009858A2/fr
Publication of WO2008009858A9 publication Critical patent/WO2008009858A9/fr
Publication of WO2008009858A3 publication Critical patent/WO2008009858A3/fr
Anticipated expiration legal-status Critical
Priority to US12/320,167 priority patent/US20090298074A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de ELOVL5 ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
PCT/FR2007/051685 2006-07-19 2007-07-18 Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée Ceased WO2008009858A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07823604A EP2046979A2 (fr) 2006-07-19 2007-07-18 Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
CA002656891A CA2656891A1 (fr) 2006-07-19 2007-07-18 Modulateurs de elovl5 dans le traitement de l'acne ou de l'hyperseborrhee
US12/320,167 US20090298074A1 (en) 2006-07-19 2009-01-21 Modulators of ELOVL5 for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653032 2006-07-19
FR0653032A FR2903998B1 (fr) 2006-07-19 2006-07-19 Modulateurs de elovl5 dans le traitement de l'acne ou de l'hyperseborrhee

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,167 Continuation US20090298074A1 (en) 2006-07-19 2009-01-21 Modulators of ELOVL5 for treating acne or hyperseborrhea

Publications (3)

Publication Number Publication Date
WO2008009858A2 WO2008009858A2 (fr) 2008-01-24
WO2008009858A9 WO2008009858A9 (fr) 2008-03-27
WO2008009858A3 true WO2008009858A3 (fr) 2008-05-08

Family

ID=37726853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051685 Ceased WO2008009858A2 (fr) 2006-07-19 2007-07-18 Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20090298074A1 (fr)
EP (1) EP2046979A2 (fr)
CA (1) CA2656891A1 (fr)
FR (1) FR2903998B1 (fr)
WO (1) WO2008009858A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938334A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938340A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la carnitine octanoyltransferase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070945A2 (fr) * 1999-05-20 2000-11-30 Karolinska Innovations Ab Genes impliques dans l'allongement des chaines d'acides gras et utilisations associees
WO2004053094A2 (fr) * 2002-12-06 2004-06-24 Ppd Development, Lp Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains
WO2005030985A2 (fr) * 2003-09-25 2005-04-07 Devgen N.V. Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070945A2 (fr) * 1999-05-20 2000-11-30 Karolinska Innovations Ab Genes impliques dans l'allongement des chaines d'acides gras et utilisations associees
WO2004053094A2 (fr) * 2002-12-06 2004-06-24 Ppd Development, Lp Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains
WO2005030985A2 (fr) * 2003-09-25 2005-04-07 Devgen N.V. Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAKOBSSON A. ET AL.: "Fatty acid elongases in mammals: Their regulation and roles in metabolism.", PROGR. LIPID RES., vol. 45, no. 3, May 2006 (2006-05-01), pages 237 - 249, XP005399132, ISSN: 0163-7827 *

Also Published As

Publication number Publication date
CA2656891A1 (fr) 2008-01-24
WO2008009858A2 (fr) 2008-01-24
FR2903998A1 (fr) 2008-01-25
US20090298074A1 (en) 2009-12-03
FR2903998B1 (fr) 2008-09-05
EP2046979A2 (fr) 2009-04-15
WO2008009858A9 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008115518A3 (fr) Biomarqueurs de l'activité sirtuine et procédés d'utilisation de ceux-ci
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
WO2012040499A3 (fr) Inhibiteurs métaboliques
MX2009007023A (es) Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2009124330A3 (fr) Traitement de maladies tumorales
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
GB201021794D0 (en) Treatment and diagnosis of behavioural disorders
WO2008115710A3 (fr) Biomarqueurs pour le cancer
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007083287A3 (fr) Procédé d'essai permettant d'évaluer l'irritation de la peau
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2007140308A3 (fr) Méthodes de criblage de modulateurs trpm4 de la sécrétion d'insuline
WO2007002188A3 (fr) Genes mptenakt en tant genes modificateurs de la voie pten/akt et methodes d'utilisation
WO2009004247A3 (fr) Inhibiteurs de tace dans le traitement de l'acne
WO2008016996A3 (fr) Procédés de modulation de la mémoire métabolique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823604

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823604

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2656891

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU